Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (6177)
All Articles published online
|
Publishing Process of This Article
|
Jan 6, 2020 (publication date) through May 2, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Clinical Cases
ISSN
2307-8960
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Cimpeanu E, Ahmed J, Zafar W, DeMarinis A, Bardarov SS, Salman S, Bloomfield D. Pembrolizumab - emerging treatment of pulmonary sarcomatoid carcinoma: A case report. World J Clin Cases 2020; 8(1): 97-102 [PMID: 31970174 DOI: 10.12998/wjcc.v8.i1.97] |
|---|---|
| URL: | https://www.wjgnet.com/2307-8960/full/v8/i1/97.htm |
| Number | Citing Articles |
| 1 |
Fengwei Kong, Weimin Wang, Longbo Gong, Wenbin Wu, Yuanyuan Liu. Anti‐PD‐1 antibody camrelizumab plus doxorubicin showed durable response in pulmonary sarcomatoid carcinoma: Case report and literature review. Journal of Clinical Pharmacy and Therapeutics 2020; 45(6): 1489 doi: 10.1111/jcpt.13234
|
| 2 |
Xuewen Liu, Fang Wang, Chunwei Xu, Xinru Chen, Xue Hou, Qian Li, Pansong Li, Zhi Xie, Yongdong Liu, Lianpeng Chang, Yanfang Guan, Xuchao Zhang, Ling Yang, Hui Wang, Xin Yi, Jianjun Zhang, Xuefeng Xia, Cesar Moran, Likun Chen. Genomic origin and intratumor heterogeneity revealed by sequencing on carcinomatous and sarcomatous components of pulmonary sarcomatoid carcinoma. Oncogene 2021; 40(4): 821 doi: 10.1038/s41388-020-01573-9
|
| 3 |
Le Wang, Jing Zhang, Xing Chen, Maoli Liang, Shuo Li, Wei Zhou, Jie Cao. Pulmonary sarcomatoid carcinoma mimicking pleural mesothelioma. Medicine 2021; 100(45): e27813 doi: 10.1097/MD.0000000000027813
|
| 4 |
Yue Zheng, Yang Fu, Qin Zhong, Rong Deng, Yu Zhang. The treatment of advanced pulmonary sarcomatoid carcinoma. Future Oncology 2022; 18(6): 727 doi: 10.2217/fon-2021-1071
|
| 5 |
Chunsen Wang, Xiang Yuan, Jianxin Xue. Targeted therapy for rare lung cancers: Status, challenges, and prospects. Molecular Therapy 2023; 31(7): 1960 doi: 10.1016/j.ymthe.2023.05.007
|
| 6 |
Yu-Feng Li, Xin-Fei Zhao, Yue Tian, Xin-Yao Xiao, Cai-Yun Yan, Hua Shen. Case Report: Pulmonary sarcomatoid carcinoma complicating TP53 mutation treated successfully with Tislelizumab combined with Anlotinib—a case report. Frontiers in Genetics 2022; 13 doi: 10.3389/fgene.2022.949989
|
| 7 |
Chia-Ling Chang, Min-Shu Hsieh, Jin-Yuan Shih, Yi-Hsuan Lee, Wei-Yu Liao, Chia-Lin Hsu, Ching-Yao Yang, Kuan-Yu Chen, Jih-Hsiang Lee, Chao-Chi Ho, Tzu-Hsiu Tsai, James Chih-Hsin Yang, Chong-Jen Yu. Real-world treatment patterns and outcomes among patients with advanced non-small-cell lung cancer with spindle cell and/or giant cell carcinoma. Therapeutic Advances in Medical Oncology 2022; 14: 175883592211338 doi: 10.1177/17588359221133889
|